Holen Sie sich die Stockscreener-App
269.42
0.01%
0.02
Illumina Inc Aktie (ILMN) Neueste Nachrichten
Illumina stock may move 9.3% on earnings release - Investing.com
Illumina: NovaSeq X And Consumables Sustain Momentum (NASDAQ:ILMN) - Seeking Alpha
Illumina (ILMN) Reports Next Week: Wall Street Expects Earnings Growth - Zacks Investment Research
Illumina (ILMN) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Illumina Jumps 5.4% Amid Sector-Wide Rally - AlphaStreet
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina’s (ILMN) Strong Quarterly Beats on Revenue and Earnings Drive Share Gains - Yahoo Finance
Illumina BioInsight Platform expands with new software to accelerate the path from sequencing to discovery - Illumina
Illumina BioInsight Platform expands with new software to accelerate the path from sequencing to discovery - PR Newswire
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Zacks Investment Research
Single Cell Sequencing Market Forecast to 2035: Services, Technologies, End-users, Applications, and Regions | 15% CAGR Drives Drug Discovery and Precision Medicine Growth - GlobeNewswire Inc.
Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
In Brief This Week: Illumina, Interpace, Ocugen, Roots, Elicera, Verily, Quantum-Si, More - GenomeWeb
Illumina, Inc. (ILMN) Options Chain - Yahoo! Finance Canada
Illumina Inc. stock underperforms Thursday when compared to competitors - MarketWatch
TD Cowen lifts target for Illumina stock to USD 270.00 - ad-hoc-news.de
Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 Million - GlobeNewswire Inc.
$100 Invested In Illumina 15 Years Ago Would Be Worth This Much Today - Benzinga
Illumina 5-Base DNA Prep with Enzymatic Fragmentation - Illumina
Illumina Debuts BioInsight Platform, Expands AI Tools for Genomic Research - marketscreener.com
Illumina Consolidates Data Analysis Products Into New Platform, Pricing Model - GenomeWeb
Press Release - Illumina
Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs - PR Newswire
Illumina, Inc. (ILMN) Launches BioInsight Platform With DRAGEN v4.6 - TradingView
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? - Zacks Investment Research
Did Illumina’s (ILMN) New SpliceAI2 Genomic Model Just Reframe Its Clinical Genomics Narrative? - Yahoo Finance
Illumina Launches $1.0 Billion Unsecured Commercial Paper Program; Signs Dealer Agreements - TradingView
Illumina Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Illumina Earnings Preview: What to Expect - Barchart.com
Should Invesco S&P MidCap Quality ETF (XMHQ) Be on Your Investing Radar? - Zacks Investment Research
Illumina’s (ILMN) Sequencing Business Is Recovering, But Is the Stock Getting Ahead of Itself? - Yahoo Finance
Introducing SpliceAI2: The Next Generation of Splicing and Transcript Isoform Prediction - Illumina
Illumina Inc (ILMN) Stock Up 5.1% but GF Value Says Overvalued -- GF Score: 65/100 - GuruFocus
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina, Inc. Stock 12‑Month Price Target Raised to $237.16, Implies 10% Downside - TradingView
What is Illumina’s (ILMN) Economic Moat, and is it Widening or Narrowing? - Yahoo Finance
Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - Investing News Network
Illumina, Inc. Initiates Recall of NovaSeq 6000Dx Including DRAGEN Server And Illumina DRAGEN Server For NextSeq 550Dx - www.marketscreener.com
Illumina Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - Illumina
Illumina releases SpliceAI2 to help advance rare disease research - Illumina
Illumina releases SpliceAI2 to help advance rare disease research - PR Newswire
After shares were delivered or withheld for exercise price or tax liability, Illumina (ILMN) CEO holds 107,770 shares. - Stock Titan
Illumina Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
She transformed genomics. Multiomics is next: The Sequence - Illumina
With voting power over 15.4M shares, FMR reports a passive stake in Illumina (ILMN). - Stock Titan
Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.
RBC raises target for Illumina stock to USD 310 - AD HOC NEWS
Illumina (ILMN) Shares Skyrocket, What You Need To Know - Yahoo Finance
1.13%
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):